Abstract
Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Current Pharmaceutical Design
Title: Molecular Pharmacology of Non-L-type Calcium Channels
Volume: 11 Issue: 15
Author(s): Clinton J. Doering and Gerald W. Zamponi
Affiliation:
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Abstract: Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Export Options
About this article
Cite this article as:
Doering J. Clinton and Zamponi W. Gerald, Molecular Pharmacology of Non-L-type Calcium Channels, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021042
DOI https://dx.doi.org/10.2174/1381612054021042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss
Current Drug Therapy Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design “Epileptic Encephalopathy” of Infancy and Childhood: Electro-Clinical Pictures and Recent Understandings
Current Neuropharmacology Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology
Current Neuropharmacology Clozapine Safety, 40 Years Later
Current Drug Safety The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Letters in Drug Design & Discovery An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Antiobesity Carbonic Anhydrase Inhibitors
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of Novel 2,3-disubstituted Benzofuran Analogues of GABA as Neurotropic Agents
Medicinal Chemistry Advances in Pediatric Epilepsy Surgery
Current Pediatric Reviews